finanzwire.de

Search

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. (FRA:NTU) Neptune Announces Third Quarter Results

Transparency directive : regulatory news

14/02/2018 21:00

14/02/2018 21:00
31/01/2018 13:00
19/01/2018 13:00
17/01/2018 13:00
11/12/2017 13:30
30/11/2017 13:00
28/11/2017 12:00
27/11/2017 13:00
14/11/2017 21:05
25/10/2017 13:00

LAVAL, QUEBEC -- (Marketwired) -- 02/14/18 -- Q3 Financial and Operational Highlights for the 3-month period ended December 31, 2017 compared to the 3-month period ended November 30, 2016(1)

--  Revenues of $7.3 million reflect a 7.5% increase in the SolutionsBusiness and the sale of the krill oil business on August 7, 2017;revenues for Q3 2017 were $12.3 million.--  Gain of $8.8 million realized from the deconsolidation of Acasti Pharma(non-control position).--  Net income of $6.0 million versus $11.2 million in the prior year in thenutraceutical segment.--  Non-IFRS operating loss(2) was $1.3 million compared to an AdjustedEBITDA(2) of $1.3 million in the prior year reflecting investment incannabis business development.--  Global MaxSimil license expanded to include cannabis-derived productsfor medical and adult use applications.--  Launch of MaxSimil-enhanced products with Charles Poliquin's StrengthSensei Nutraceuticals.

Post Quarter End Highlights:

--  Co-development, commercialization and marketing agreement with TetraBio-Pharma Inc. for purified cannabinoid oil-based products targeted forpain and inflammation announced on February 12, 2018.--  Research agreement to develop new medical and wellness targetedcannabinoid oil-based products with krill oil announced on January 19,2018.(1)  Neptune Nutraceutical Segment.(2)  See "Caution Regarding Non-IFRS Financial Measures" and "Reconciliationof net income (loss) to Adjusted EBITDA or non-IFRS operating loss"which follow.

Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ: NEPT)(TSX: NEPT), today announced its financial and operating results for the 3-month and 9-month periods ended December 31, 2017. All amounts are in Canadian dollars.

"In our third quarter, we executed well against our strategic growth initiative to enter the cannabis business and further expanded our solutions business. Leveraging our proven expertise across multiple skillsets in science, regulation, formulation and commercialization, I am pleased to report that all the elements of our cannabis growth plan are solidly on track," said Jim Hamilton, President and Chief Executive Officer of Neptune.

"Since our business review meeting last November, we have been very busy with business development activities, including discussions with potential suppliers, site preparation, and progress toward securing licenses," added Mr. Hamilton. "In addition, we have conducted numerous solvent trials, intended to prove the effectiveness of this approach for cannabis oil extraction, which have yielded promising results. Concurrently, we recently entered into research and development partnerships that will facilitate the commercialization of clinically proven value-added products for the cannabis space, ones that will be differentiated by our extraction, purification and formulation expertise."

"Our Solutions Business revenue, supported by the growth of our MaxSimil delivery platform, increased 7.5% versus the prior year's quarter and 2.6% sequentially," said Mr. Hamilton. "Based on our current backlog of business, we expect a very strong fourth quarter in this business. As a result, we remain confident that we will achieve our stated goal of double-digit revenue growth in the segment for the full year."

Concluded Mr. Hamilton, "As we come to the end of a major transition year for Neptune, the foundational building blocks for our cannabis initiative have been put into place, upon which we will build the framework to take us to a new level of growth and profitability. We are fielding a strong experienced team, have identified all the necessary steps to complete the journey and are confident we can bring highly differentiated products to the market. We look forward to updating you on our progress over the ensuing quarters through news releases about our business developments and milestone achievements."

Nutraceutical Business Results

As previously announced, Neptune transitioned to a new fiscal year-end as at March 31, 2017. Financial information for the three-month and nine-month periods ended December 31, 2016 has not been included in these financial statements for the following reasons: (i) the three-month and nine-month periods ended November 30, 2016 provide a meaningful comparison for the three-month and nine-month periods ended December 31, 2017; (ii) there are no significant factors, seasonal or otherwise, that would impact the comparability of information if the results for the three-month and nine-month periods ended December 31, 2016 were presented in lieu of results for the three-month and nine-month periods ended November 30, 2016; and (iii) it was not practicable or cost justified to prepare this information.

Third Quarter Financial Results

--  Nutraceutical revenues were $7.3 million for the three-month periodended December 31, 2017, versus $12.3 million for the three-month periodended November 30, 2016.--  Net income was $6.0 million for the current quarter, versus $11.2million in the prior year.--  Non-IFRS operating loss(1) was $1.3 million for the current quarter,compared to an Adjusted EBITDA(1) of $1.3 million in the prior year.

The nutraceutical segment third quarter Non-IFRS operating loss(1) increase was mainly attributable to the sales and gross margin decrease after the transaction concluded with Aker BioMarine. The nutraceutical segment third quarter net income includes a gain on loss of control of a subsidiary of $8.8 million.

Year-to-Date Financial Results

--  Nutraceutical revenues were $20.6 million for the nine-month periodended December 31, 2017, versus $35.1 million for the nine-month periodended November 30, 2016.--  Net income was $24.8 million for the nine-month period ended December31, 2017, versus $9.3 million in the prior year.--  Non-IFRS operating loss(1) was $0.8 million for the nine-month periodended December 31, 2017, compared to an Adjusted EBITDA(1) of $3.2million in the prior year.

The nutraceutical segment Year-to-Date Non-IFRS operating loss(1) increase was mainly attributable to the sales and gross margin decrease after the transaction concluded with Aker BioMarine. The nutraceutical segment Year-to-Date net income includes a gain on sale of assets of $23.7 million, a gain on loss of control of a subsidiary of $8.8 million and impairment loss on inventories of $1.7 million.

Consolidated Results (including Acasti Pharma until the loss of control on December 27, 2017)

Third Quarter Financial Results

--  Consolidated revenues totalled $7.3 million for the three-month periodended December 31, 2017, versus $12.1 million for the three-month periodended November 30, 2016.--  Net income was $1.3 million for the current quarter, versus $9.4 millionin the prior year.--  Non-IFRS operating loss(1) was $5.4 million for the current quarter,versus $0.5 million in the prior year.

On a consolidated basis, until the loss of control on December 27, 2017, the current quarter includes a Non-IFRS operating loss(1) of $4.2 million and a net loss of $5.2 million for Neptune's subsidiary, Acasti, which is actively engaged in clinical studies and research and development. For the three-month period ended November 30, 2016, Acasti recorded a Non-IFRS operating loss(1) of $1.7 million and a net loss of $2.4 million.

Year-to-Date Financial Results

--  Consolidated revenues were $20.6 million for the nine-month period endedDecember 31, 2017, versus $35.0 million for the nine-month period endedNovember 30, 2016.--  Net income was $14.1 million for the nine-month period ended December31, 2017, versus $3.2 million in the prior year.--  Non-IFRS operating loss(1) was $10.5 million for the nine-month periodended December 31, 2017, compared to $2.5 million in the prior year.

On a consolidated basis, until the loss of control on December 27, 2017, the nine-month period ended December 31, 2017 includes a Non-IFRS operating loss(1) of $9.7 million and a net loss of $12.5 million for Neptune's subsidiary, Acasti, which is actively engaged in clinical studies and research and development. For the nine-month period ended November 30, 2016, Acasti recorded a Non-IFRS operating loss(1) of $5.6 million and a net loss of $7.9 million.

Cash and cash equivalents, including $2.4 million of restricted short-term investments, were $28.6 million as at December 31, 2017.

(1)  See "Caution Regarding Non-IFRS Financial Measures" and "Reconciliationof net income (loss) to Adjusted EBITDA or non-IFRS operating loss"which follow.

Caution Regarding Non-IFRS Financial Measures

The Corporation uses an adjusted financial measure, Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) called non-IFRS operating loss when the Corporation or segment is in a loss position, to assess its operating performance. This non-IFRS financial measure is directly derived from the Corporation's financial statements and is presented in a consistent manner. The Corporation uses this measure for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. This measure also helps the Corporation to plan and forecast for future periods as well as to make operational and strategic decisions. The Corporation believes that providing this information to investors, in addition to IFRS measures, allows them to see the Corporation's results through the eyes of management, and to better understand its historical and future financial performance.

Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Adjusted EBITDA (or non-IFRS operating loss when in a loss position) to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Corporation believes it provides meaningful information on the Corporation financial condition and operating results. Neptune's method for calculating Adjusted EBITDA (or non-IFRS operating loss) may differ from that used by other corporations.

Neptune obtains its Adjusted EBITDA (or non-IFRS operating loss) measurement by adding to net income (loss), finance costs, depreciation, amortization and impairment loss and income taxes and by subtracting finance income. Other items such as stock-based compensation, insurance recoveries from plant explosion, royalty settlements, net gain on sale of krill oil business, legal fees related to royalty settlements, gain on loss of control of subsidiary, tax credits recoverable from prior years and acquisition costs that do not impact core operating performance of the Corporation are excluded from the calculation as they may vary significantly from one period to another. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivatives. Excluding these items does not imply they are non-recurring.

Conference Call Details

Neptune will be holding a conference call on February 14, 2018, at 5:00 PM (EST) to discuss its third quarter results for the three-month and nine-month periods ended December 31, 2017.

Date:     Wednesday, February 14, 2018Time:     5:00 PM Eastern Standard TimeCall:     1 (877) 223-4471 (within Canada & the U.S.)1 (647) 788-4922 (Outside Canada and the U.S.)Webcast:  A live audio webcast and presentation of the results can beaccessed at: http://neptunecorp.com/en/investors/events-and-presentations/

A replay of the call will be available for replay two hours after the call's completion, until March 14, 2018. The telephone numbers to access the replay of the call are 1 (416) 621-4642 or 1 (800) 585-8367 (toll-free), Conference ID 7495706. The archive of the webcast, along with its accompanying presentation, will also be made available immediately in the Investors section of Neptune's website under Investor Events and Presentations.

About Neptune Technologies & Bioressources Inc.

Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company formulates and provides turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products.

The Company's head office is located in Laval, Quebec.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form (the "AIF"), which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunecorp.com. All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors" and in our MD&A for the interim period ended December 31, 2017 under "Risks and uncertainties".

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

Reconciliation of net income (loss) to non-IFRS operating loss(1)(Expressed in thousands of dollars)Three-month period ended December 31, 2017--------------------------------------------------------------------------------------------------------------------------------------------------------Inter-segmentNutraceutical  Cardiovascular  eliminations    Total--------------------------------------------------------------------------------------------------------------------------------------------------------$               $             $        $----------------------------------------------------------------------------Total revenues                 7,315               -             -    7,315Gross margin                   2,015               -             -    2,015R&D expenses (i)              (1,785)         (4,285)          581   (5,489)R&D tax credits andgrants                           12              24             -       36SG&A                          (2,477)           (908)            -   (3,385)Other income - net gainon sale of assets              (147)              -             -     (147)Loss from operatingactivities                   (2,382)         (5,169)          581   (6,970)Gain on loss of controlof the subsidiaryAcasti                        8,783               -             -    8,783Net finance cost                (396)            (21)           (2)    (419)Income taxes                     (53)              -             -      (53)Net income (loss)              5,952          (5,190)          579    1,341--------------------------------------------------------------------------------------------------------------------------------------------------------Non-IFRS operatingloss(1) calculationNet income (loss)              5,952          (5,190)          579    1,341Add (deduct):Depreciation andamortization                  763             670          (581)     852Finance costs                  487              67             -      554Finance income                 (91)             (9)            -     (100)Change in fair valueof derivative assetsand liabilities                 -             (37)            2      (35)Stock-basedcompensation                  199             330             -      529Income taxes                    53               -             -       53Gain on loss ofcontrol of thesubsidiary Acasti          (8,783)              -             -   (8,783)Other income - netgain on sale ofassets                        147               -             -      147----------------------------------------------------------------------------Non-IFRS operatingloss(1)                      (1,273)         (4,169)            -   (5,442)--------------------------------------------------------------------------------------------------------------------------------------------------------(i)  These R&D expenses of the Nutraceutical segment include $1,730 of costsassociated to the cannabis business.(1)  See "Caution Regarding Non-IFRS Financial Measures".Reconciliation of net income (loss) to Adjusted EBITDA(1) or non-IFRSoperating loss(1)(Expressed in thousands of dollars)Three-month period ended November 30, 2016--------------------------------------------------------------------------------------------------------------------------------------------------------Inter-segmentNutraceutical  Cardiovascular  eliminations    Total--------------------------------------------------------------------------------------------------------------------------------------------------------$               $             $        $----------------------------------------------------------------------------Total revenues                12,252               1          (112)  12,141Gross margin                   3,450               1             1    3,452R&D expenses                    (349)         (1,708)          581   (1,476)R&D tax credits andgrants                            9              24             -       33SG&A                          (4,511)           (829)            -   (5,340)Other income - royaltysettlement                   13,117               -             -   13,117Income (loss) fromoperating activities         11,716          (2,512)          582    9,786Net finance income(cost)                         (697)            115             -     (582)Income taxes                     217               -             -      217Net income (loss)             11,236          (2,397)          582    9,421--------------------------------------------------------------------------------------------------------------------------------------------------------Adjusted EBITDA(1)(non-IFRS operatingloss)(1) calculationNet income (loss)             11,236          (2,397)          582    9,421Add (deduct):Depreciation andamortization                  856             621          (581)     896Finance costs                  625               1            (6)     620Finance income                (126)           (118)            6     (238)Change in fair valueof derivative assetsand liabilities               198               2             -      200Stock-basedcompensation                  315             155             -      470Income taxes                  (217)              -             -     (217)Royalty settlement         (13,117)              -             -  (13,117)Legal fees related toroyalty settlement          1,501               -             -    1,501----------------------------------------------------------------------------Adjusted EBITDA(1 )(non-IFRS operatingloss)(1)                      1,271          (1,736)            1     (464)--------------------------------------------------------------------------------------------------------------------------------------------------------(1)  See "Caution Regarding Non-IFRS Financial Measures".

Reconciliation of net income (loss) to non-IFRS operating loss(1)(Expressed in thousands of dollars)Nine-month period ended December 31, 2017--------------------------------------------------------------------------------------------------------------------------------------------------------Inter-segmentNutraceutical  Cardiovascular  eliminations    Total--------------------------------------------------------------------------------------------------------------------------------------------------------$               $             $        $----------------------------------------------------------------------------Total revenues                20,640               -             -   20,640Gross margin                   4,866               -             -    4,866R&D expenses (i)              (2,572)         (9,676)        1,742  (10,506)R&D tax credits andgrants                           62              84             -      146SG&A                          (8,274)         (2,761)            -  (11,035)Other income - net gainon sale of assets            23,724               -             -   23,724Income (loss) fromoperating activities         17,806         (12,353)        1,742    7,195Gain on loss of controlof the subsidiaryAcasti                        8,783               -             -    8,783Net finance cost              (1,719)           (121)           (7)  (1,847)Income taxes                     (40)              -             -      (40)Net income (loss)             24,830         (12,474)        1,735   14,091Total assets                  93,678           6,079             -   99,757Cash, cash equivalentsand restricted short-term investments             28,586               -             -   28,586Working capital(2)            29,945               -             -   29,945--------------------------------------------------------------------------------------------------------------------------------------------------------Non-IFRS operatingloss(1) calculationNet income (loss)             24,830         (12,474)        1,735   14,091Add (deduct):Depreciation andamortization                2,511           2,005        (1,742)   2,774Finance costs                1,984             355             -    2,339Finance income                (108)            (38)            -     (146)Change in fair valueof derivative assetsand liabilities              (156)           (196)            7     (345)Stock-basedcompensation                  781             661             -    1,442Income taxes                    40               -             -       40Impairment loss oninventories                 1,719               -             -    1,719Gain on loss ofcontrol of thesubsidiary Acasti          (8,783)              -             -   (8,783)Other income - netgain on sale ofassets                    (23,724)              -             -  (23,724)Legal fees related toroyalty settlements            90               -             -       90----------------------------------------------------------------------------Non-IFRS operatingloss(1)                        (816)         (9,687)            -  (10,503)--------------------------------------------------------------------------------------------------------------------------------------------------------(i)  These R&D expenses of the Nutraceutical segment include $1,730 of costsassociated to the cannabis business.(1)  See "Caution Regarding Non-IFRS Financial Measures".(2)  The working capital is presented for information purposes only andrepresents a measurement of the Corporation's short-term financialhealth mostly used in financial circles. The working capital iscalculated by subtracting current liabilities from current assets.Because there is no standard method endorsed by IFRS, the results maynot be comparable to similar measurements presented by other publiccompanies.Reconciliation of net income (loss) to Adjusted EBITDA(1) or non-IFRSoperating loss(1)(Expressed in thousands of dollars)Nine-month period ended November 30, 2016--------------------------------------------------------------------------------------------------------------------------------------------------------Inter-segmentNutraceutical  Cardiovascular  eliminations    Total--------------------------------------------------------------------------------------------------------------------------------------------------------$               $             $        $----------------------------------------------------------------------------Total revenues                35,093               8          (112)  34,989Gross margin                   9,554               8             1    9,563R&D expenses                  (1,119)         (5,747)        1,742   (5,124)R&D tax credits andgrants                           28              70             -       98SG&A                         (10,197)         (2,252)            -  (12,449)Other income - royaltysettlement                   13,117               -             -   13,117Income (loss) fromoperating activities         11,383          (7,921)        1,743    5,205Net finance income(cost)                       (1,982)             41            (3)  (1,944)Income taxes                     (83)              -             -      (83)Net income (loss)              9,318          (7,880)        1,740    3,178Total assets                 101,628          21,589       (13,175) 110,042Cash, cash equivalentsand restricted short-term investments              6,759           5,843             -   12,602Working capital(2)            15,628           4,421             1   20,050--------------------------------------------------------------------------------------------------------------------------------------------------------Adjusted EBITDA(1)(non-IFRS operatingloss)(1) calculationNet income (loss)              9,318          (7,880)        1,740    3,178Add (deduct):Depreciation andamortization                2,388           1,843        (1,742)   2,489Finance costs                1,976              15           (89)   1,902Finance income                (226)             40            89      (97)Change in fair valueof derivative assetsand liabilities               233             (96)            3      140Stock-basedcompensation                  985             430             -    1,415Income taxes                    83               -             -       83Royalty settlement         (13,117)              -             -  (13,117)Legal fees related toroyalty settlement          1,501               -             -    1,501Acquisition costs               38               -             -       38----------------------------------------------------------------------------Adjusted EBITDA(1)(non-IFRS operatingloss)(1)                      3,179          (5,648)            1   (2,468)--------------------------------------------------------------------------------------------------------------------------------------------------------(1)  See "Caution Regarding Non-IFRS Financial Measures".(2)  The working capital is presented for information purposes only andrepresents a measurement of the Corporation's short-term financialhealth mostly used in financial circles. The working capital iscalculated by subtracting current liabilities from current assets.Because there is no standard method endorsed by IFRS, the results maynot be comparable to similar measurements presented by other publiccompanies.

Contacts:
Neptune Wellness Solutions
Mario Paradis
VP & CFO, Neptune
1.450.687.2262 x236
m.paradis@neptunecorp.com

Investor Relations Contact (Canada)
Pierre Boucher
MaisonBrison
1.514.731.0000
pierre@maisonbrison.com

Investor Relations Contact (U.S.)
Ed McGregor/Jody Burfening
LHA, IR
1.212.838.3777
emcgregor@lhai.com